Related by context. All words. (Click for frequent words.) 73 CR nPR 70 CCyR 70 pCR 70 ACR# response 70 HBeAg seroconversion 70 DAS# CRP 70 mcg albinterferon alfa 2b 69 achieved ACR# 69 certolizumab 69 % Confidence Interval 68 sustained virological response 68 chlorambucil 68 somatostatin analog 68 complete cytogenetic response 68 annualized relapse 68 MCyR 68 CR CRu 68 ALT elevation 68 ACR# responses 67 relapsed MM 67 lumbar spine BMD 67 % CI #.#-#.# [007] 67 achieved CCyR 67 Crohn Disease Activity 67 complete cytogenetic 67 PSA nadir 67 CRp 67 HOMA IR 67 ACR Pedi 66 HBeAg negative patients 66 μmol L 66 preoperative PSA 66 cytogenetic response 66 tipranavir r 66 mL/min/#.# m 2 66 abacavir lamivudine 66 microbiological eradication 66 8mg/kg 66 PASI scores 66 p = NS 66 μg liter 66 Index CDAI 66 undetectable HBV DNA 66 lymphocytosis 66 seroprotection 66 elevated ALT 66 progression TTP 66 leukocyte count 66 Scale EDSS 66 nondiabetic patients 66 Aptivus ® 66 postintervention 66 adalimumab 65 methotrexate monotherapy 65 Kaplan Meier estimates 65 response CCyR 65 PREZISTA r arm 65 VELCADE melphalan 65 REYATAZ r arm 65 ULORIC 65 EDSS scores 65 biochemical relapse 65 fluticasone salmeterol 65 HER2 expression 65 oxycodone CR 65 BENICAR HCT 65 mcg BID 65 Operative mortality 65 intact parathyroid hormone 65 Flu Cy 65 nodular partial response 65 CIMZIA TM 65 hematological parameters 65 pmol L 65 DAS# [002] 65 ACTEMRA TM 65 plus dexamethasone 65 definite stent thrombosis 65 receiving APTIVUS r 65 pT3 65 XIENCE V PROMUS Stent 65 serum urate 65 salmeterol fluticasone 65 endoscopic remission 64 remission CR 64 alanine aminotransferase ALT 64 MADRS score 64 clinically meaningful improvement 64 SVR# 64 #.#mg/dL 64 Doxil ® 64 BENICAR 64 % CI #.#-#.# [003] 64 posttreatment 64 statistical significance p 64 baseline FEV 64 mg BID dose 64 titrated glipizide 64 mcg QD 64 SGPT 64 albumin excretion rate 64 serum phosphate 64 sUA 64 mg QD 64 CDAI 64 liver histology 64 TLUS 64 CIMZIA ™ 64 Psoriasis Area 64 plus methotrexate 64 mITT population 64 prospectively defined 64 -#.# log# 64 HBeAg positive patients 64 SCr 64 secondary efficacy endpoint 64 RECIST criteria 64 mRCC 64 galiximab 64 alanine aminotransferase 64 EDSS score 64 mRS 64 PEG IFN 64 4mg/kg 63 periprocedural 63 prospectively stratified 63 tapentadol ER 63 Median PFS 63 APTIVUS r 63 Pharmacokinetic parameters 63 rFSH 63 Expanded Disability Status 63 IRLS score 63 baseline LDH 63 PegIFN RBV 63 bortezomib refractory 63 Response Evaluation Criteria 63 Teriflunomide 63 serum concentrations 63 ipsilateral stroke 63 venlafaxine XR 63 echocardiographic parameters 63 PSADT 63 histologically confirmed 63 NIHSS 63 antibody titer 63 Secondary endpoints include 63 binary restenosis 63 DLTs 63 salmeterol fluticasone propionate 63 rizatriptan 63 serum phosphorus 63 Free Survival PFS 63 Sustained virologic response 63 haematologic 63 prednisone prednisolone plus 63 adjunctive placebo 63 mcg mL 63 aspartate aminotransferase 63 p = #.# [003] 63 EURIDIS 63 clinicopathological features 63 ACR# ACR# 63 Kaplan Meier analysis 63 microbiologically evaluable 63 mg/m2 dose 63 RECIST Response Evaluation Criteria 63 heavily pretreated 63 radiographic progression 63 serologically active patients 63 fludarabine cyclophosphamide 63 receiving golimumab 63 -#.# log# copies mL 63 ALT elevations 63 ADCS CGIC 63 splenectomized patients 63 ADAS cog 63 SGRQ 63 severe exacerbations 63 median PFS 63 cEVR 63 desvenlafaxine succinate 63 EBMT criteria 63 ACR# [002] 63 Hb A1C 63 decitabine 63 locoregional recurrence 62 Solid Tumors criteria 62 interquartile range 62 Severity Index PASI 62 Partial Response 62 lopinavir r arm 62 sustained virologic response 62 Stent thrombosis 62 DAS# scores 62 evaluable subjects 62 glycated hemoglobin levels 62 CsA 62 BARACLUDE ® 62 achieved sustained virological 62 baseline HbA1c 62 CC genotype 62 oral diclofenac 62 hours postdose 62 AST ALT 62 estimated glomerular filtration 62 aspartate aminotransferase AST 62 nmol liter 62 comparator arm 62 TEAEs 62 urinary N telopeptide 62 anemia hemoglobin 62 % CI #.#-#.# [008] 62 FDA defined valvulopathy 62 arterial thromboembolic events 62 gemcitabine carboplatin 62 achieved sustained virologic 62 Scale EDSS score 62 viral kinetics 62 budesonide pMDI 62 p ≤ 62 seropositivity 62 peginterferon alfa 2a 62 Primary endpoints 62 elevated LDH 62 imipenem 62 mg p = 62 HbA1C levels 62 daunorubicin 62 FluCAM 62 alicaforsen enema 62 ug kg 62 biologic DMARD 62 #mg dose [002] 62 IOP lowering 62 HDRS 62 virologic suppression 62 demonstrated clinically meaningful 62 mmol l 62 statistically significant p = 62 confidence interval #.#-#.# 62 mg/m2/day 62 VaD 62 timepoints 62 Cmax 62 serum ALT 62 T2DM 62 -#.# ± [002] 62 log# reduction 62 serum HBV DNA 62 preintervention 62 fosamprenavir 62 imatinib therapy 62 piperacillin tazobactam 62 tigecycline 62 adjunctive ABILIFY 62 mg ustekinumab 62 glycated hemoglobin 62 PsA 62 microg 62 TIMP 1 62 serum cortisol 62 mg kg dose 62 LV ejection fraction 62 virologic response 62 Kaplan Meier 62 glycosylated hemoglobin HbA1c 62 CANCIDAS 62 morphometric vertebral fractures 62 Montgomery Åsberg Depression 62 mg TID 62 lactate dehydrogenase LDH 62 HBeAg 62 conventional DMARDs 62 symptomatic intracranial hemorrhage 62 Rating Scale MADRS 62 HAQ DI 62 NMIBC 62 mg BID 62 pT2 62 MMSE score 62 Score TOS 62 pegylated interferon alfa 62 Hycamtin ® 62 calculated creatinine clearance 62 MACCE 62 Lupuzor ™ 62 octreotide LAR 62 TURBT 61 clinically evaluable patients 61 tocilizumab 61 BMI z 61 gemcitabine cisplatin 61 balsalazide 61 multivariate Cox 61 estramustine 61 #ng/ml 61 advanced adenoma 61 glomerular filtration 61 pg mL 61 serum CRP 61 perioperatively 61 CDAI score 61 #mg BID [001] 61 serum testosterone 61 angiographic restenosis 61 log# copies mL 61 CI #.#-#.# [001] 61 HGPIN 61 virologic failure 61 mL kg 61 Rating Scale BPRS 61 tipranavir ritonavir 61 FOLPI 61 AUC0 61 Castration Resistant Prostate Cancer 61 highly emetogenic 61 RECIST 61 CK # plasma concentrations 61 melphalan prednisone 61 hip BMD 61 ECOG PS 61 Non Responders 61 aminotransferase levels 61 prostate cancer CaP 61 X ULN 61 metastatic CRC 61 mCi kg 61 doxorubicin cyclophosphamide 61 adefovir treated 61 Pred Forte 61 serum urate levels 61 plasma HCV RNA 61 evaluating tivozanib 61 deep venous thromboses 61 seropositive patients 61 Tumor shrinkage 61 plus MTX 61 #μg [002] 61 infliximab monotherapy 61 hepatorenal syndrome 61 nicardipine 61 noninferiority 61 lispro 61 reduce serum phosphate 61 elevated transaminases 61 thrombosis embolism 61 #mg/m# [001] 61 ALT flares 61 FFNS 61 Solid Tumors RECIST 61 irbesartan 61 q#h 61 corticosteroid dose 61 plus prednisone 61 HSCT 61 refractory NSCLC 61 CIMZIA TM certolizumab pegol 61 achieved PASI 61 lymphocyte count 61 Serum creatinine 61 mucosal healing 61 confidence intervals CIs 61 STELARA ® 61 thyroglobulin 61 Pemetrexed 61 dose dependently 61 tumor histology 61 univariate analysis 61 SSRI SNRI 61 ertapenem 61 metastatic malignant 61 Timed Walk 61 plus prednisone prednisolone 61 histological subtype 61 Severity MSCS score 61 Brief Psychiatric 61 IU ml 61 serum phosphate levels 61 Ishak fibrosis score 61 bendamustine 61 Rate ORR 61 transaminase elevations 61 abacavir Ziagen 61 ritonavir boosted 61 achieving PASI 61 Hazard Ratio 61 ADCS ADL 61 multivariate analyzes 61 biochemical recurrence 61 CHOP chemotherapy 61 oral allopurinol 61 CYT# QbG# 61 ADAS Cog 61 histologic subtype 61 atazanavir ritonavir 61 evaluable patients 61 adriamycin 61 radical prostatectomy RP 61 interferon alfa 2b 61 apolipoprotein B 61 ug ml 61 null responder 61 ara C 61 β blockers 61 MAGE A3 ASCI 61 neoadjuvant chemotherapy 61 attain statistical significance 61 mitoxantrone 61 colorectal adenoma 61 stage IIIB 61 interferon ribavirin 61 Etanercept 61 prolactin elevation 61 #mg/m# [002] 61 AGILECT R 61 ATACAND 61 IBDQ 61 IFN alfa 60 SSc 60 serum phosphorous 60 HbA 1c levels 60 recurrent glioblastoma multiforme 60 undetectable HCV RNA 60 tacrolimus ointment 60 follicular lymphomas 60 NovoSeven ® 60 MoxDuo TM IR 60 detectable HCV RNA 60 biliary tract cancer 60 FOLFOX4 60 Febrile neutropenia 60 ug dose 60 lamivudine refractory patients 60 ALT normalization 60 plus COPEGUS 60 Pegylated Liposomal Doxorubicin 60 QTcF 60 Ejection Fraction 60 plasma cortisol 60 efavirenz EFV 60 K ras mutations 60 LEXIVA r 60 GnRH agonist 60 IELT 60 hip resurfacing arthroplasty 60 achieve sustained virologic 60 placebo p = 60 macroalbuminuria 60 pharmacodynamic PD 60 Soft Tissue Sarcoma 60 reinfarction 60 confirmed CCyR 60 neurologic progression 60 ARB telmisartan 60 zoledronate 60 biopsy Gleason 60 Y BOCS 60 corrected QT interval 60 mg qd 60 tumor regressions 60 median survivals 60 UPDRS 60 CLL SLL 60 -#.# mg dL [002] 60 Decitabine 60 SLNB 60 multivariable analysis 60 active comparator 60 CK MB 60 gefitinib Iressa 60 chemoradiation therapy 60 mIU mL 60 WOMAC pain 60 mg/m2 cohort 60 oxcarbazepine 60 serum creatinine levels 60 response pCR 60 Montgomery Asberg Depression 60 Non inferiority 60 plasma leptin 60 mL/min/#.# m2 60 noninferior 60 peginterferon alfa 2b 60 serum aminotransferase levels 60 pulmonary exacerbations 60 cisplatin gemcitabine 60 Engerix B 60 teriflunomide 60 creatinine ratio 60 CTEPH 60 Taxol ® 60 lopinavir r 60 uM 60 IFN α 60 CNS LS 60 cranial irradiation 60 6MWD 60 HbA 1c 60 flutamide 60 CrCl 60 LV dysfunction 60 nonmetastatic 60 DOXIL 60 metastatic GIST 60 subcutaneously administered 60 paraprotein 60 R# #mg BID 60 evaluable 60 unfractionated heparin UFH 60 XELOX 60 recurrent VTE 60 mg Proellex 60 Score DAS# 60 Secondary endpoints 60 sirolimus stent 60 recurrent GBM 60 Hazard Ratio HR 60 dapagliflozin plus 60 Subgroup analysis 60 PRADAXA #mg 60 Secondary endpoints included 60 microvessel density 60 radical nephrectomy 60 neuropathy sensory 60 tolterodine ER 60 prolactin levels 60 iPTH 60 UPDRS scores 60 EDSS 60 primary patency 60 plasma renin activity 60 HCV genotype 60 tirofiban 60 oral prednisolone 60 Mg Uk 60 EBRT 60 Natalizumab 60 placebo dexamethasone 60 latanoprost 60 XIENCE V demonstrated 60 mITT 60 PANSS 60 Peg IFN 60 ribavirin RBV 60 rimonabant #mg 60 #mg/day [001] 60 BEXXAR Therapeutic Regimen 60 p = .# [002] 60 nonfatal MI 60 HBeAg + 60 albumin excretion 60 ARCOXIA 60 μg kg 60 carotid stenosis 60 lactate dehydrogenase 60 pamidronate 60 oxycodone IR 60 #mg QD [002] 60 fasting plasma glucose FPG 60 resectable 60 ibandronate 60 TAXUS p value 60 serum parathyroid hormone 60 ‰ ¥ 60 univariate analyzes 60 #mg/day [002] 60 hemoglobin Hb 60 euthyroid 60 COPAXONE R 60 % CI #.#-#.# [001] 60 dose Iluvien 60 clodronate 60 ng dL 60 beta 1a 60 interquartile range IQR 60 clinicopathological 60 bronchial hyperresponsiveness 60 posaconazole 60 CVD mortality 60 R0 resection 60 NIHSS score 60 antiretroviral naive 60 #Gy 60 NPH insulin 60 treatment naive genotype 60 DAPT 60 mild renal insufficiency 60 tertiles 60 virologic breakthrough 60 q8h 60 selective modulator 60 #.#ng/ml 60 linaclotide treated 60 glomerular filtration rate 59 Aflibercept 59 achieved statistical significance 59 prucalopride 59 Solid Tumors 59 tumor progression TTP 59 locoregional disease 59 goserelin 59 hyperphenylalaninemia HPA due 59 troponin T 59 icatibant 59 mitoxantrone plus 59 anagrelide 59 caspofungin 59 tobramycin inhalation solution 59 briakinumab 59 postprocedure 59 specific antigen PSA 59 genotypic resistance 59 plus OBT 59 Sustained Virological Response 59 tipranavir 59 PCWP 59 neoadjuvant 59 graft occlusion 59 glatiramer acetate 59 postoperative mortality 59 mCRPC 59 risedronate 59 vWF 59 DMARD 59 RE LY ® 59 plasma folate 59 TMC# r 59 HBeAg negative 59 sensory neuropathy 59 urinary albumin excretion 59 elevated creatinine 59 NNT = 59 bronchodilation 59 COPD exacerbations 59 LB# [003] 59 xanthine oxidase inhibitor 59 severe neutropenia 59 efficacy evaluable 59 carboplatin paclitaxel 59 alteplase 59 5-FU/LV 59 FOLFIRI 59 Folfox 59 MIRAPEX 59 serum triglycerides 59 nmol L. 59 sd = 59 HAM D# scores 59 timolol 59 -#.# mg dL [001] 59 Platelet counts 59 Xalatan R 59 mean baseline HbA1c 59 GSK# [001] 59 Arch Intern Med 59 virological response 59 lacosamide 59 MDRD 59 olmesartan 59 pelvic lymphadenectomy 59 TIMP 59 HBV DNA levels 59 oblimersen 59 adalimumab Humira 59 advanced hepatocellular carcinoma 59 paclitaxel eluting stents 59 non squamous histology 59 NYHA functional class 59 nadroparin 59 micrograms mL 59 hemoglobin A1c HbA1c 59 transaminases 59 infliximab 59 MIC# [001] 59 EGFR TKI 59 Plaque Psoriasis 59 aminotransferases 59 hematopoietic cancers 59 pimecrolimus cream 59 P = .# 59 postdose 59 SSRI citalopram 59 etanercept 59 CIN2 + 59 moderate renal impairment 59 CI -#.# 59 ABC/3TC 59 oocytes retrieved 59 platelet reactivity 59 TAXUS Express Stent 59 hepatic fibrosis 59 eosinophil count 59 CIMZIA R 59 #OHD levels 59 periprocedural MI 59 YMRS 59 dexamethasone Decadron 59 Bezielle 59 mesalamine granules 59 antiangiogenic therapy 59 neoadjuvant treatment 59 sargramostim 59 cells uL 59 glycated hemoglobin HbA1c 59 ZOMIG Nasal Spray 59 receiving SIMPONI 59 CD3 + 59 Baseline characteristics 59 CLARITY study 59 QIDS SR 59 neutrophil counts 59 Visual Analogue Scale VAS 59 peginterferon alfa 2a #KD 59 systolic dysfunction 59 mU liter 59 #mg q8h 59 HES CEL 59 nonobese 59 ispinesib administered 59 amoxicillin clavulanate 59 vidofludimus 59 relapsing multiple sclerosis 59 Fulvestrant 59 endometrial thickness 59 MabCampath 59 ABVD 59 A1c levels 59 Plasma concentrations 59 postmenopausal osteoporotic women 59 chloride secretion 59 partial remissions 59 neutropenia dehydration dyspnea 59 pegylated liposomal doxorubicin 59 5 Fluorouracil 59 Virulizin ® 59 Relapsing Remitting Multiple Sclerosis 59 abnormal p# biomarker 59 PREZISTA ritonavir 59 TACE 59 serum calcium levels 59 IFN beta 59 logistic regression analyzes 59 ischemia driven 59 seroprotective 59 plus medroxyprogesterone acetate 59 ZACTIMA 59 INVEGA ® 59 umol L 59 HT 1A 59 azacitidine 59 serum estradiol 59 paricalcitol 59 Cardiorespiratory fitness 59 mcg dose 59 baseline serum creatinine 59 mycophenolate mofetil 59 postoperative chemotherapy 59 ExTRACT TIMI 59 drotrecogin alfa activated 59 GOUT 59 adjuvant systemic 59 NIH CPSI 59 completely resected 59 oxaliplatin Eloxatin 59 T1c 59 locoregional 59 placebo fluoxetine 59 resected pancreatic cancer 59 mutated KRAS 59 thalidomide dexamethasone 59 HCV replicon 59 Endothelial dysfunction 59 airway hyperresponsiveness 59 log# IU mL 59 inhaled iloprost 59 LPV r 59 clinically meaningful improvements 59 EXJADE 59 univariate 59 = #.#-#.# 59 Cariprazine 59 STRIDE PD 59 CTAP# Capsules 59 dasatinib Sprycel 59 nonresponders 59 fraction LVEF 59 androgen suppression 59 OGTT 59 candesartan cilexetil 59 sitaxsentan 59 Am J Cardiol 59 recurrent venous thromboembolism 59 Target Lesion Revascularization TLR 59 Hypotension 59 Fasting blood glucose 59 pancreatic adenocarcinoma 59 ± SEM 59 TOP2A 59 Pharmacokinetics PK 59 vincristine doxorubicin 59 receiving prophylactic anticoagulation 59 ximelagatran 59 placebo p 59 mg q#h 59 T2 lesions 59 thromboembolic events 59 Zemplar Capsules 59 HbA 1C 59 clinico pathological 59 mmHg diastolic 59 atorvastatin #mg 59 μg mL 59 steroid dexamethasone 59 Cinacalcet HCl 59 cytogenetic responses 59 #mg BID [003] 59 donepezil Aricept 59 CIN3 59 unstable angina pectoris 59 dalteparin 59 elevated troponin 59 CYT# potent vascular disrupting 59 erection hardness 59 Lenalidomide 59 Double Blind Randomized 59 ß blockers 59 chemoradiotherapy 59 #F FDG PET 59 Subgroup analyzes 58 methacholine challenge 58 oral rivaroxaban 58 advanced adenomas 58 intraobserver 58 visceral metastases 58 POAG 58 % CI #.#-#.# [006] 58 CI #.#-#.# [002] 58 dosing cohort 58 LH FSH 58 TYGACIL 58 PANSS scores 58 hypophosphatemia 58 intima media thickness 58 DFMO 58 μg L 58 saline placebo 58 Durezol 58 cinacalcet 58 INCB# [003] 58 Ziprasidone 58 enalapril 58 ng dl 58 tamsulosin 58 amprenavir 58 humanized interleukin 6 58 cabazitaxel 58 recurrent genital herpes 58 KRAS mutations occur 58 linezolid 58 idarubicin 58 pyrexia mucositis sepsis febrile 58 EGFR mutation positive 58 standard chemotherapy regimen 58 nab paclitaxel 58 antiandrogen 58 Postoperative complications 58 vasopressor 58 mcg kg 58 liver metastasis 58 oral antidiabetic medication 58 microgram kg 58 extracapsular extension 58 Scale cognitive subscale 58 lowest tertile 58 paroxysmal AF 58 azilsartan medoxomil 58 ARCALYST ® 58 relapsed refractory multiple myeloma 58 undetectable viral 58 dasatinib Sprycel ® 58 atheroma volume 58 Index CDAI score 58 Taxotere ® 58 P ≤ 58 Fludara 58 μg dose 58 KRAS mutant tumors 58 peginterferon alfa 58 cytarabine daunorubicin 58 atherogenic dyslipidemia 58 ACZ# 58 mcg linaclotide 58 free survival PFS 58 serum IGF 58 iodixanol 58 Hemodialysis Patients 58 interferon alfa 58 hematologic toxicity 58 lumiliximab 58 Raptiva r 58 antiarrhythmic drug 58 colorectal liver metastases 58 nonvertebral 58 oral vancomycin 58 perioperative complications 58 clomipramine 58 Navelbine 58 QVAR R 58 Qmax 58 sleeve lobectomy 58 aged ≥ 58 cardiovascular calcification 58 STN stimulation 58 polyp recurrence 58 bisoprolol 58 leukemia AML 58 ejection fractions 58 g dl 58 Telintra 58 intravenous dosing 58 DLQI 58 micafungin 58 papillary thyroid carcinoma 58 HIV coinfected 58 mg administered orally 58 FUSILEV enhances 58 interferon beta therapy 58 nonvertebral fractures 58 pharmacokinetic characteristics 58 sinus rhythm 58 leucopenia 58 serum prostate 58 imiquimod cream 58 transaminase levels 58 BUPHENYL R sodium phenylbutyrate 58 IPSS 58 #mg #mg #mg [003] 58 hsCRP levels 58 beta blocker therapy 58 patients evaluable 58 myelodysplastic myeloproliferative diseases 58 IL#B 58 adenoma recurrence 58 pharmacokinetic PK profile 58 metastatic renal cell carcinoma 58 thromboembolic 58 thrombocytopenic 58 x ULN 58 malignancy HCM 58 hematologic parameters 58 adiponectin concentrations 58 gm dl 58 TNF antagonist 58 Cholinesterase Inhibitors 58 pretreatment baseline 58 fluoxetine paroxetine 58 Disease Activity 58 Renal Cell Carcinoma RCC 58 anti leukemic 58 MADRS 58 pegIFN 58 sorafenib Nexavar ® 58 Lubiprostone 58 hypogonadal men 58 doripenem 58 refractory AML 58 Stage IIB 58 alemtuzumab treated 58 stomatitis pharyngitis 58 coronary stenosis 58 isoenzyme 58 limiting toxicity 58 affective psychosis 58 Kinoid 58 ritonavir boosted atazanavir 58 SCIg 58 mm Stent 58 systemic corticosteroid 58 neoadjuvant therapy 58 #.#/#.# mmHg [001] 58 FIRMAGON 58 PANSS total 58 epirubicin cyclophosphamide 58 BARACLUDE r 58 apremilast 58 UACR 58 unresectable tumors 58 Randomized Evaluation 58 virologic responses 58 IM progesterone 58 esophageal carcinoma 58 3mg/kg 58 oral Hycamtin 58 circulating EPCs 58 heterozygotes 58 fluvastatin 58 serum BDNF 58 elevated IOP